Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.

Montgomery KG, Chang JH, Gertig DM, Dite GS, McCredie MR, Giles GG, Southey MC, Hopper JL, Campbell IG.

Breast Cancer Res. 2005;7(3):R353-6. Epub 2005 Mar 4.

2.

The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.

Colilla S, Kantoff PW, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Brown M, Weber BL, Rebbeck TR.

Carcinogenesis. 2006 Mar;27(3):599-605. Epub 2005 Oct 22.

PMID:
16244359
3.

Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.

Hsing AW, Chokkalingam AP, Gao YT, Wu G, Wang X, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Chiang T, Chen YL, Stanczyk FZ, Chang C.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):337-41.

4.

Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.

Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M.

Cancer Res. 2001 Jul 15;61(14):5420-4.

5.

Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.

Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):127-35.

6.

The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G; Australian Breast Cancer Family Study; Australian Jewish Breast Cancer Study; Breast Cancer Family Registry; Interdisciplinary Health Research International Team on Breast Cancer Susceptibility; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer; Epidemiological Study of Familial Breast Cancer Study Collaborators.

Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):76-9.

7.

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.

Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L, Gaborieau V, Bressac-de-Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S, Sobol H, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Yannoukakos D, Mazoyer S, Lynch HT, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM.

Int J Cancer. 2005 Nov 1;117(2):230-3.

8.

The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years.

Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, Giles GG, Ellis-Steinborner S, Venter DJ, Newman B, Southey MC, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):413-6.

9.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS.

J Natl Cancer Inst. 2002 Dec 4;94(23):1773-9.

PMID:
12464649
11.

Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.

Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, Venter DJ, Hopper JL.

J Natl Cancer Inst. 2003 Mar 19;95(6):448-57.

PMID:
12644538
12.

AIB1 polymorphisms with breast cancer susceptibility: a pooled analysis of variation in BRCA1/2 mutation carriers and non-carriers.

Zhang Y, Huang M, Zhu Z.

Mol Biol Rep. 2012 Jun;39(6):6881-6. doi: 10.1007/s11033-012-1514-2. Epub 2012 Feb 4.

PMID:
22307791
13.

CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.

Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles RA.

Br J Cancer. 2001 Jul 6;85(1):36-40.

14.
15.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
16.

Polyglutamine repeat length in the NCOA3 does not affect risk in familial breast cancer.

Wilkening S, Burwinkel B, Grzybowska E, Klaes R, Pamula J, Pekala W, Zientek H, Hemminki K, Försti A.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):291-2. No abstract available.

17.

The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study.

Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW, Hunter DJ.

Cancer Res. 2002 Feb 15;62(4):1045-9.

18.

Rapid detection of CAA/CAG repeat polymorphism in the AIB1 gene using DHPLC.

Kleibl Z, Havranek O, Prokopcova J.

J Biochem Biophys Methods. 2007 Apr 10;70(3):511-3. Epub 2006 Dec 9.

PMID:
17234271
19.
20.

Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years.

Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE, Chy H, Trute L, McCredie MR, Giles GG, Armes J, Venter DJ, Hopper JL, Chenevix-Trench G.

J Natl Cancer Inst. 1999 Jun 2;91(11):961-6.

PMID:
10359549

Supplemental Content

Support Center